Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2008

Molli Poonam R, Adam Liana, Kumar Rakesh

Abstract excerpt

PURPOSE: Abnormalities in the expression and signaling pathways downstream of epidermal growth factor receptor (EGFR) contribute to progression, invasion, and maintenance of the malignant phenotype in human cancers. Accordingly, biological agents, such as the EGFR-blocking antibody IMC-C225 have promising anticancer potential and are currently in various stages of clinical development. Because use of IMC-C225 is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytoskeleton

Share to Epidermal Growth Factor

Share to Neoplasm Invasiveness

Share to Proto-Oncogene Proteins c-vav

Share to rho GTP-Binding Proteins

Share to rhoA GTP-Binding Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 18829495
DOI: 10.1158/1078-0432.CCR-07-5288
PMCID: PMC3151536

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.PMID 18829495Read ↗

Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer CellsSemantic proximity Read ↗

c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.Semantic proximity Read ↗

Extradomain-B Fibronectin is a molecular marker of invasive breast cancer cellsSemantic proximity Read ↗

The role of talin2 in breast cancer tumorigenesis and metastasisSemantic proximity Read ↗

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.Semantic proximity Read ↗

Design and Evaluation of Eb4Mab-7-mG2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer TherapySemantic proximity Read ↗

Fibronectin as target for tumor therapySemantic proximity Read ↗

Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic nicheSemantic proximity Read ↗

Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategySemantic proximity Read ↗

Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.Semantic proximity Read ↗

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.Semantic proximity Read ↗

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.